Ginkgo Bioworks (DNA) Q4 2025 earnings review
A Radical Shrink to Survive: Slashing Costs and Divesting Biosecurity
Ginkgo Bioworks is aggressively downsizing its legacy businesses to fund a full pivot toward autonomous, AI-driven laboratories. Q4 total revenue decelerated sharply, falling 24% YoY to $33 million, as both the core Cell Engineering and Biosecurity segments contracted. However, the aggressive 2025 restructuring paid off on the bottom line: Adjusted EBITDA loss narrowed significantly to $(36) million from $(57) million a year ago. In a major strategic move, Ginkgo is spinning off its Biosecurity business to private investors to exclusively funnel its remaining $423 million cash pile into its 'frontier autonomous lab' in Boston and AI partnerships.
🐂 Bull Case
FY25 Adjusted EBITDA loss improved drastically to $(167) million from $(293) million in FY24. The 2026 cash burn guidance of $125M-$150M implies a clear path to survival given the $423M cash balance.
By spinning off Biosecurity and decommissioning legacy manual lab benches, Ginkgo focuses entirely on high-margin, scalable autonomous lab infrastructure and cloud lab services with partners like OpenAI.
🐻 Bear Case
The core Cell Engineering segment fell 26% YoY to $26M in Q4. Ginkgo is sacrificing current revenue streams for a future automated business model that has yet to prove it can scale commercially.
Transitioning from a 'Solutions' provider to a 'Tools & Automation' vendor is historically difficult. If biopharma customers hesitate to adopt Reconfigurable Automation Carts (RACs), Ginkgo's entire thesis stalls.
⚖️ Verdict: ⚪
Neutral. The financial discipline is impressive and necessary, but Ginkgo is effectively restarting as an automation startup. Until the new autonomous lab sales replace the rapidly declining legacy services revenue, it remains a 'show-me' story.
Key Themes
Biosecurity Divestiture Clears the Deck
Reversing its previous multi-pillar strategy, Ginkgo is spinning off its Biosecurity business into a standalone private entity backed by defense tech investors. Ginkgo will retain a minority stake. This removes a volatile segment that relied heavily on unpredictable government funding and frees up capital strictly for the autonomous lab strategy.
OpenAI and the Autonomous 'Cloud Lab'
Accelerating its AI narrative, Ginkgo revealed a collaboration with OpenAI using GPT-5 to design experiments via Ginkgo's cloud lab. This resulted in a 40% improvement over state-of-the-art Cell-Free Protein Synthesis. This specific data point validates the 'hands for the AI brain' thesis, proving that physical automation can successfully interface with cutting-edge reasoning models.
Core Cell Engineering Contraction
Decelerating sharply, Q4 Cell Engineering revenue dropped 26% YoY to $26 million. While management attributes this to 'ongoing program rationalization' and a shift from early-stage to large enterprise customers, the sheer volume of the drop indicates that legacy customers are churning faster than the new 'Datapoints' and 'Automation' offerings can replace them.
Hardware as a Service: RAC Installations
Stable momentum in the physical automation deployment. Ginkgo is building and installing customized Reconfigurable Automation Carts (RACs) directly at customer sites. A key proof point is the recent completion of an 18-instrument autonomous anaerobic system for the Pacific Northwest National Laboratory, which subsequently led to a massive $47M contract for a 97-instrument lab.
Defense Tech & Macro Pivot Vulnerability
Ginkgo explicitly noted rising interest in 'defense tech' as a reason for spinning out Biosecurity. However, navigating the macroeconomic reality of tighter U.S. R&D budgets means the company's $180M+ government backlog (historically spanning ARPA-H and BARDA) remains vulnerable to shifts in federal budgetary priorities.
Datapoints Market Penetration
Stable early adoption. The 'Datapoints' business—providing AI-ready biological datasets as a service—worked with 10 top pharma customers in its first full year. This indicates real demand for 'onshored', high-volume, fee-for-service biological data generation, offsetting weakness in traditional royalty-based R&D partnerships.
Other KPIs
Accelerating improvement. Operating cash burn roughly halved from $(319.6) million in FY24 to $(171.1) million in FY25. This underscores the brutal but effective $250M annualized cost-cutting program initiated in mid-2024.
Decelerating. Down from $462M at the end of Q3 2025 and $602M at the end of FY24. However, the sequential decline is slowing, providing a multi-year runway to execute the automation pivot without immediate dilution risk.
Decelerating. G&A expenses dropped 25% YoY from $246.2 million in FY24, serving as the primary driver behind the massive improvement in Adjusted EBITDA. This reflects successful headcount reductions and facility footprint consolidation.
Guidance
Accelerating improvement vs FY25's $(171) million operating cash outflow. At the $(137.5) million midpoint, Ginkgo demonstrates it can significantly stretch its $423M cash pile through at least 2028, reducing existential panic.
Key Questions
Biosecurity Spinoff Economics
With the divestiture of the Biosecurity unit, what is the specific minority equity percentage Ginkgo will retain, and will there be any ongoing cash obligations to support the new private entity?
Autonomous Lab Revenue Ramp
As legacy Cell Engineering revenues decline during program rationalization, what is the expected timeline for RAC installations and cloud lab services to become the majority revenue engine?
OpenAI Partnership Monetization
The GPT-5 integration showed a 40% improvement in CFPS. Does this technical milestone translate directly into a joint go-to-market strategy with OpenAI, or is it strictly an internal R&D capability proof point?